Can a new drug tame vasculitis with fewer side effects?
NCT ID NCT05897684
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This study tracks the safety of avacopan, a medication for ANCA-associated vasculitis, an autoimmune disease that causes blood vessel inflammation. Researchers will compare side effects like liver injury, heart problems, serious infections, and cancer in people taking avacopan versus those on standard treatments. The goal is to see if avacopan offers a safer long-term option for managing this serious condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- avacopan
- What this could lead to
- If avacopan proves safer than current therapies, it could become a preferred treatment for ANCA-associated vasculitis.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. The results may take years to emerge.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbrookes Hospital
Cambridge, United Kingdom
-
Barts Health
London, United Kingdom
-
Bradford Teaching Hospitals NHS Foundation Trust
Bradford, United Kingdom
-
Cardiff and Vale UHB
Cardiff, United Kingdom
-
Charité University Medicine
Berlin, Germany
-
East Kent Hospitals University NHS FT
Canterbury, United Kingdom
-
Epsom & St. Helier NHS Trust
Carshalton, United Kingdom
-
Hammersmith Hospital, Imperial College Healthcare NHS Trust
London, United Kingdom
-
KRH Klinikum Siloah
Hanover, Germany
-
Kings College Hospital
London, United Kingdom
-
LMU
Munich, Germany
-
Manchester University NHS Foundation Trust
Manchester, United Kingdom
-
Medius Kliniken
Plochingen, Germany
-
Municipal Hospital Dresden
Dresden, Germany
-
NHS Greater Glasgow & Clyde
Glasgow, United Kingdom
-
North Bristol NHS Trust
Bristol, United Kingdom
-
Northern Care Alliance
Salford, United Kingdom
-
Nottingham university hospitals NHS trust
Nottingham, United Kingdom
-
Rheumatology Department, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
-
Rheumazentrum Ruhrgebiet
Herne, Germany
-
Royal Berkshire NHS foundation trust
Reading, United Kingdom
-
Royal Devon University Healthcare NHS Foundation Trust
Exeter, United Kingdom
-
Royal Free
London, United Kingdom
-
St Thomas' Hospital
London, United Kingdom
-
St. Josef-Stift Sendenhorst
Sendenhorst, Germany
-
Swansea Bay University LHB
Swansea, United Kingdom
-
UHB NHS Foundation Trust
Birmingham, United Kingdom
-
University Hospital Eppendorf
Hamburg, Germany
-
University Hospital Essen
Essen, Germany
-
University Hospital Freiburg
Freiburg im Breisgau, Germany
-
University Hospital of Cologne
Cologne, Germany
-
University Hospitals Coventry and Warwickshire
Coventry, United Kingdom
-
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
-
University Medical Center Göttingen
Göttingen, Germany
-
York & Scarborough Teaching Hospitals NHS FT
York, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at autoimmune kidney diseases
- Could a diabetes drug shield kidneys from autoimmune attack?
- Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
- New tool could predict who will suffer from steroid side effects
- Immune cell therapy takes on kidney disease
- Scientists launch biobank to unlock secrets of rare vasculitis